|Videos|January 16, 2018

What Is "Lyme Anxiety?"

Leonard Sigal, MD, explains the term “Lyme anxiety” and its association with a chronic Lyme disease diagnosis.

Leonard Sigal, MD, clinical professor and former chief of the Division of Rheumatology at Robert Wood Johnson UMDNJ Medical School, explains the term “Lyme anxiety” and its association with a chronic Lyme disease diagnosis.

Interview Transcript (modified slightly for readability):

“Lyme anxiety: the anxiety related to Lyme disease, usually related to the diagnosis of chronic Lyme disease. So, somebody walks into the office with erythema migrans, who’s done a little bit of research, and says, ‘That. That’s Lyme disease, isn’t it?’ And I say, ‘Yep. We’re going to give you some antibiotics and you’re going to get better.’ And the overwhelming majority of people in that setting do get better.

It’s the person who walks in with vague complaints, no physical findings, nothing that I can say, ‘That’s what it is.’ It’s a vague constellation of complaints. Those people, somebody has told that that it’s Lyme disease; it might have been at the grocery checkout; they might have been looking at something on the internet; they might have been going to a physician who claims that it’s chronic Lyme disease. And then they would wind up coming to me at the referral center that I used to run at Robert Wood Johnson.

And they’re scared out of their minds because they think ‘I’ve had this disease for who knows how long. Look what it’s doing to me. I’m not going to be around to watch my children grow up.’ People’s anxiety runs wild. Should you be concerned if you have Lyme disease? Sure. Is there reason to be afraid of it? A little bit, sure. But to approach hysteria is in nobody’s best interest and it’s really unnecessary. And it’s really one of the really toxic consequences of this ongoing debate about chronic Lyme disease.”


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.